Chromosome conformation signatures define predictive markers of inadequate response to methotrexate in early rheumatoid arthritis

Abstract excerpt

BACKGROUND: There is a pressing need in rheumatoid arthritis (RA) to identify patients who will not respond to first-line disease-modifying anti-rheumatic drugs (DMARD). We explored whether differences in genomic architecture represented by a chromosome conformation signature (CCS) in blood taken from early RA patients before methotrexate (MTX) treatment could assist in identifying non-response to DMARD and,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Chronic Myeloid Leukemia Treatments
• Share to Genetic Associations and Epidemiology
• Share to Rheumatoid Arthritis Research and Therapies